Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016 Kerry Rowe

Abstract from Movement Disorders Conference 2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Alterity PBT434 Poster Presented at 2019 MDS Congress

October 3, 2019October 10, 2019

Alterity Therapeutics Presents to Finance News Network

June 4, 2019June 4, 2019

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

June 23, 2021July 15, 2021

Recent Posts

New Publication Demonstrates ATH434 is Neuroprotective
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s
European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
Alterity Therapeutics to Present at the MST Access Australian Micro & Small Caps Conference
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065